Targeted Genetics has raised $11.2 million in an initial public offering of 2 million shares of common stock. The Seattle-based company is developing products to help reinforce impaired immune systems. It has started two clinical trials on potential treatments for patients infected with HIV, the virus that causes AIDS. It also is developing therapies that use stem cells, the primative cells that mature into all types of blood cells, including white blood cells.
Vector Healthsystems, Providence, R.I., last month added the Georgia Hospital Association's 188 members to its purchasing program. Vector is one of the founding members of AmeriNet, a purchasing group of more than 2,800 healthcare facilities. The GHA expects its members to buy about $8 million in goods and services through the affiliation agreement. Previously, the Marietta, Ga.-based association didn't have a group purchasing function.